Therapeutic potential of lipid nanosystems for the treatment of Parkinson's disease

Subham Preetam; Swathi Jonnalagadda; Lamha Kumar; Rajeswari Rath; Soham Chattopadhyay; Badrah S Alghamdi; Adel M Abuzenadah; Niraj Kumar Jha; Akash Gautam; Sumira Malik; Ghulam Md Ashraf

doi:10.1016/j.arr.2023.101965

Therapeutic potential of lipid nanosystems for the treatment of Parkinson's disease

Ageing Res Rev. 2023 Aug:89:101965. doi: 10.1016/j.arr.2023.101965. Epub 2023 May 31.

Authors

Affiliations

¹ Institute of Advanced Materials, IAAM, Gammalkilsvägen 18, Ulrika, 59053, Sweden; Centre for Biotechnology, Siksha O Anusandhan (SOA-DU), Bhubaneswar 751030, Odisha, India. Electronic address: sspritamrath93@gmail.com.
² School of Biology, Indian Institute of Science Education and Research, Thiruvananthapuram, India. Electronic address: swathi21@iisertvm.ac.in.
³ School of Biology, Indian Institute of Science Education and Research, Thiruvananthapuram, India. Electronic address: lamhakumar@gmail.com.
⁴ Centre for Biotechnology, Siksha O Anusandhan (SOA-DU), Bhubaneswar 751030, Odisha, India. Electronic address: rajeswarirath24@gmail.com.
⁵ Department of Zoology, Maulana Azad College, Kolkata, Kolkata-700013, West Bengal, India. Electronic address: soham6904@gmail.com.
⁶ Department of Physiology, Neuroscience Unit, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; Pre-Clinical Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia. Electronic address: basalghamdi@kau.edu.sa.
⁷ King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia; Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. Electronic address: aabuzenadah@kau.edu.sa.
⁸ Department of Biotechnology, School of Engineering and Technology, Sharda University, Greater Noida 201310, India; Department of Biotechnology, School of Applied & Life Sciences (SALS), Uttaranchal University, Dehradun 248007, India; School of Bioengineering & Biosciences, Lovely Professional University, Phagwara 144411, India; Department of Biotechnology Engineering and Food Technology, Chandigarh University, Mohali, 140413, India. Electronic address: niraj.jha@sharda.ac.in.
⁹ Centre for Neural and Cognitive Sciences, University of Hyderabad, Hyderabad 500046, India. Electronic address: akash@uohyd.ac.in.
¹⁰ Amity Institute of Biotechnology, Amity University Jharkhand, Ranchi, Jharkhand, 834001, India; Guru Nanak College of Pharmaceutical Sciences, Chakrata Road, Jhajra, Dehradun 248007, India. Electronic address: smalik@rnc.amity.edu.
¹¹ University of Sharjah, College of Health Sciences, and Research Institute for Medical and Health Sciences, Department of Medical Laboratory Sciences. Electronic address: gashraf@sharjah.ac.ae.

PMID: 37268112
DOI: 10.1016/j.arr.2023.101965

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disorder. The degeneration of dopaminergic neurons in the midbrain is primarily responsible for the onset of the disease. The major challenge faced in the treatment of PD is the blood-brain barrier (BBB), which impedes the delivery of therapeutics to targeted locations. To address this issue, lipid nanosystems have been used for the precise delivery of therapeutic compounds in anti-PD therapy. In this review, we will discuss the application and clinical significance of lipid nanosystem in delivering therapeutic compounds for anti-PD treatment. These medicinal compounds include ropinirole, apomorphine, bromocriptine, astaxanthin, resveratrol, dopamine, glyceryl monooleate, levodopa, N-3,4-bis(pivaloyloxy)- dopamine and fibroblast growth factor, which have significant potential to treat PD in the early stage. This review, in a nutshell, will pave the way for researchers to develop diagnostic and potential therapeutic approaches using nanomedicine to overcome the challenges posed by the BBB in delivering therapeutic compounds for PD.

Keywords: Lipid nanosystems; Nanomedicine; Neurodegeneration; Parkinson's diesae; Therapeutics.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Dopamine
Humans
Levodopa / therapeutic use
Lipids
Neurodegenerative Diseases*
Parkinson Disease* / drug therapy

Substances

Dopamine
Levodopa
Lipids